Given the variability in CYP-mediated cannabinoid metabolism, personalized medicine approaches are essential for optimizing cannabinoid therapy and cannabinoid-associated coagulopathy, particularly in the context of neurodegenerative diseases. This evidence concerns the gene PPIG and neurodegenerative disease.